We are a purpose-driven team, passionate about developing innovative, patented, FDA-approved serotonergic psychedelic therapeutic solutions for underserved mental health disorders, beginning with postpartum depression (PPD) and adjustment disorder (AjD). Leveraging our team’s extensive experience in neuroscience drug development, we are advancing RE104, a patented, clinical-stage drug candidate designed as a safe, fast-acting, short duration therapy for patients with underserved mental health disorders. RE104, the only 4-OH-DiPT prodrug in clinical development, is being evaluated in the RECONNECT Phase 2 clinical trial as a potential treatment for PPD and in the planned REKINDLE Phase 2 clinical trial as a potential treatment for AjD in cancer and other medical illnesses.
In addition to advancing our lead candidate, RE104, we are developing RE245, a discovery-stage, non-psychedelic asset, for application in chronic treatment paradigms and indications. RE245 is structurally similar to classic psychedelics and is designed to have selective potency at the target serotonin 2A receptor (5HT2A), without off-target 5HT2B receptor agonism.